Though immunotherapies targeting the PD1/PD-L1 immune checkpoint pathway have been FDA-approved for treatment of advanced MCC11,12, a significant proportion of MCC patients are either resistant to immune checkpoint blockade or unsuitable for immunotherapy due to autoimmune or immunosuppressed conditions1. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.